We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byOlivia Jacoway
Modified over 2 years ago
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD, FACC, Christopher P. Cannon MD FACC, Sabina A. Murphy MPH, Jie Qin MS, Kausik K. Ray MD, Eugene Braunwald MD, MACC for the PROVE IT-TIMI 22 Investigators Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.
Background and Objectives The PROVE IT-TIMI 22 trial demonstrated that LDL-C < 70 mg/dL was associated with greater CHD event reduction than LDL-C <100 mg/dL after ACS. n We evaluated the impact of TG in the PROVE IT-TIMI 22 trial, reasoning that if high LDL-C and TG increases CHD risk more than isolated high LDL-C, then the combination of low on- treatment LDL-C and TG would be associated with reduced CHD risk compared to low LDL-C (< 70 mg/dL) alone. Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply
Methods n Study Population: 4,162 patients in The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) trial n Blood Sampling: Plasma samples for lipids, lipoproteins, HS-CRP at baseline, 30 d, and 4, 8, 16, 24 months Composite Endpoint: Death, myocardial infarction (MI) or recurrent ACS between 30 d and 2 yr follow-up Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.
Methods (2) Statistical Analysis Kaplan-Meier event rates after censoring events within 30 days of initial ACS event. Cox proportional hazards model: Age, gender, DM, HTN, obesity (BMI > 30 kg/m 2 ), cigarette smoking (active), low HDL-C to estimate effect of on-treatment LDL-C (70 mg/dL) and TG (150 mg/dL) within 30 days or 4 months of initial ACS event. CRP (2 mg/L) included to assess triple goal attainment Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.
Results Days After Month 1 Visit TG < 150 TG ≥ 150 HR: 0.73 (0.62, 0.87) P < Days After Month 1 Visit LDL < 70 LDL ≥ 70 HR: 0.81 (0.68, 0.96) P = Kaplan-Meier Estimates Based on LDL-C < 70 mg/dL or TG < 150 mg/dL Between 30 days and 2 yr Follow-Up Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.
Results TG < 150TG ≥ 150 LDL-C < 70 LDL-C ≥ 70 Rate of Death, MI or Recurrent ACS after 30 days Adjusted for age, sex, smoking, DM, HTN, obesity, HDL, PVD, prior ACS, prior statin use and treatment effect Hazard of Death, MI & Recurrent ACS with on-treatment LDL-C (70 mg/dL) & TG (150 mg/dL) Ref 17.9% 15.0% 16.5% 11.7% P = P = P = HR: 0.84 ( ) HR: 0.85 ( ) HR: 0.72 ( ) Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.
Results Proportion of Pravastatin (40 mg) and Atorvastatin (80 mg) Treated Patients Attaining LDL-C < 70, CRP < 2 & TG < 150 at 30 days Proportion of on-treatment 35%* * P < between the treatment groups 6.6% Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply.
Results Hazard of death, MI and recurrent ACS with number of goals achieved based on LDL-C < 70, CRP < 2 & TG < 150 mg/dL at 30 d 35%* 6.6% Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply. Adjusted for age, sex, smoking, DM, HTN, obesity, HDL, PVD, prior ACS, prior statin use and treatment effect
On-treatment TG < 150 mg/dL was associated with a lower risk of recurrent CHD events independently of the level of LDL-C. Therefore, these data lend support to the concept that achieving both a low LDL-C and low TG may be important therapeutic parameters following ACS Miller et al. J Am Coll Cardiol 2008;51: Copyright ©2008 American College of Cardiology Foundation. Restrictions may apply. Conclusions
How Aggressive do we get on Lipids? Christopher Cannon, M.D. Senior Investigator, TIMI Study Group Cardiovascular Division, Brigham and Women’s Hospital,
Niacin Use in Patients with Low HDL-Cholesterol Receiving Intensive Statin Therapy William E. Boden, MD, FACC, FAHA Jeffrey Probstfield, MD, FACC, FAHA.
© 2010 CV Health: Three Ways to ‘kNOw’ Kathleen O’Neil-Smith, MD Malden, MA.
P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Insights from clinical trials: The unassailable case for LDL-c.
Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes Results From the A to Z Trial JA de Lemos, DA Morrow, SA Wiviott,
Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
Lipid Disorders and Management in Diabetes Om P. Ganda MD Joslin Diabetes Center Harvard Medical school Boston, MA Web-conference, April 8, 2010.
Reduction in Total (First and Recurrent) Cardiovascular Events with Ezetimibe/Simvastatin compared with Simvastatin Alone post ACS in the IMPROVE-IT Trial.
Secretory Phospholipase A2: A New Risk Factor and Soon a New Target of Therapy Rabih R. Azar, MD, MSc, FACC Associate Professor of Medicine Division of.
PEACE BNP: Omland, T. et al. J Am Coll Cardiol 2007; 50:205–14 Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Prognostic.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Next Steps in Primary Prevention of Coronary Heart.
Simulations The basics for simulations. Simulation is a way to model random events, such that simulated outcomes closely match real-world outcomes. By.
TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130 250 mg/dL following up to 8-week washout and 8-week.
Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD.
Schutzvermerk nach DIN 34 beachten 05/04/15 Seite 1 Training EPAM and CANopen Basic Solution: Password * * Level 1 Level 2 * Level 3 Password2 IP-Adr.
Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
The IDEAL Cholesterol Christopher Cannon, M.D. TIMI Study Group Brigham and Women’s Hospital Cannon CP. JAMA 2005;294:
NCEP ATP III Cholesterol Guidelines and Updates Anoop Agrawal, M.D. Med-Peds Continuity Clinic Baylor College of Medicine.
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels Frank M. Sacks, M.D., Marc A. Pfeffer,
Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome <10 days and Total Cholesterol < 240 mg/dL ASA + Standard Medical Therapy.
VBWG BRAVER Trial BRachial Artery Vascular Endothelium Reactivity Study A substudy of PROVE IT-TIMI 22.
Raphael See, Shuaib Abdullah, Darren K. McGuire, Amit Khera, Mahesh J. Patel, Jason B. Lindsey, Scott M. Grundy, James A. de Lemos J Am Coll Cardiol 2007;50:752-9.
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
1 1 = = = = = 6.
1 1 = = = 18 9 = 30 5 = = 36 9 =
Chapter 12 Static Equilibrium; Elasticity and Fracture Physics for Scientists & Engineers, 3 rd Edition Douglas C. Giancoli © Prentice Hall.
EuroCondens SGB E. Elementy obudowy kotła
Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.
AGVISE Laboratories %Zone or Grid Samples – Northwood laboratory % Grid or Zone Samples Tested Compared To Conventional Whole Field Composite.
Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Optimal low-density lipoprotein is 50 to 70 mg/dl:
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years total cholesterol 25%; LDL.
Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
I 1. can 2 see 3 A 4 to 5 come 6 my 7 the 8.
BRIAN CLAYTON INTERNAL MEDICINE ADVISOR: ANNA MAE SMITH PRECEPTOR: DR. RAJESH PATEL Evidence Based Medicine Spring 2009.
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol VA-HIT Rubins, HB, et.
Jacqueline Saw, MD*, Danielle Brennan, MS †, Steven Steinhubl, MD ‡, Deepak L. Bhatt, MD †, Koon-Hou Mak, MD §, Keith Fox, MB^, and Eric J. Topol, MD #
LIPID LOWERING IN T2D (The Lower the Better?) CONS… TARGETING HARD CVD END POINTS Charles SAAB MD Consultant Endocrinologist DCRP Sacre-Coeur University.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
Trend for Precision Soil Testing % Zone or Grid Samples Tested compared to Total Samples.
Treating to New Targets Study TNT Trial Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa.
Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10):
Dyslipidemia and Cardiovascular Risk Reduction: An Evidence-Based Review Robert M. Guthrie, MD Professor of Emergency Medicine Professor of Internal Medicine.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Metabolic & Endocrine Disease Summit Dyslipidemia and Current Guidleines for Lipid Management Thursday July 28, 2011 Orlando, FL Joyce L. Ross, MSN, CRNP,
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Plasma triglycerides and type III hyperlipidemia.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
A Fractional Order (Proportional and Derivative) Motion Controller Design for A Class of Second-order Systems Center for Self-Organizing Intelligent Systems.
Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Test in Context: High-Sensitivity C-Reactive Protein.
© 2017 SlidePlayer.com Inc. All rights reserved.